Biocon Ltd's Q3FY25 Quarter Results - kotaksecurities.com

Jan 31, 2025 · Biocon Ltd reported a 6.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a …

CouponFollow Extension

4%
OFF

Biocon Ltd's Q3FY25 Quarter Results - Kotaksecurities.com

2 weeks from now

Jan 31, 2025 · Biocon Ltd reported a 6.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a …

kotaksecurities.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …

2 weeks from now

Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

biocon.com

96%
OFF

Biocon Q3 Results: Profit Plummets 96%; Misses Estimates

2 weeks from now

Jan 30, 2025 · Biocon Ltd.'s Q3FY25 consolidated net profit plummeted 96% to Rs 25 crore, falling short of analysts' estimates. ... Biocon Q3 FY25 Results Highlights (Consolidated, YoY) …

ndtvprofit.com

5%
OFF

Biocon's Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

Jan 30, 2025 · The company's quarterly results were also impacted due to tax expenses, Biocon said. The company increased its equity shareholding in its biologics unit by 1.5% for 5.6 billion …

reuters.com

14%
OFF

Biocon Ltd (BOM:532523) Q3 2025 Earnings Call Highlights: Strong ...

2 weeks from now

Feb 1, 2025 · Biocon Ltd achieved key product approvals in both biologics and generics, with new product launches planned for Q4. The biosimilars segment showed a 14% year-on-year …

yahoo.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs …

2 weeks from now

5 Reported EBITDA for Q3FY25 was Rs 487 crore, including a non-cash forex translation loss of Rs 20 crore. Excluding the forex impact, EBITDA margin for the quarter was 22%.On a like-for …

biocon.com

7%
OFF

Q3FY25 Quarterly Result Announced For Biocon Ltd. - Trendlyne

2 weeks from now

Jan 31, 2025 · Biotechnology company Biocon announced Q3FY25 results Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore. Reported 7% YoY growth on a like-for-like basis, …

trendlyne.com

44%
OFF

Biocon Quarterly Results, Biocon Financial Statement & Accounts

2 weeks from now

Get Biocon latest Quarterly Results, Financial Statements and Biocon detailed profit and loss accounts. ... Biocon Ltd. Biocon Ltd. | BSE 357.15 1.55 (0.44%) | NSE 357.00 1.30 (0.37%) | …

moneycontrol.com

5%
OFF

Biocon Buys Back An Investor Stake In Biologics Unit, Posts Rs 25 …

2 weeks from now

Jan 30, 2025 · Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, …

indiatimes.com

FAQs about Biocon Ltd's Q3FY25 Quarter Results - kotaksecurities.com Coupon?

How did Biocon perform in Q3 FY22?

Biocon's consolidated Q3FY22 revenues grew by 18% YoY to Rs 2,223 crore. The company reported a net profit of Rs 187 crore, up 11% YoY. Biocon's performance was driven by a strong showing across all business segments: Biosimilars grew by 28% to Rs 981 crore, Research Services was up 10% at Rs 641 crore, and Generics delivered a 7% growth at Rs 607 crore, according to Kiran Mazumdar-Shaw, executive chairperson of Biocon. ...

What was Biocon's net profit in q3fy25?

Bengaluru-based biopharma firm Biocon on Thursday reported a consolidated net profit of Rs 25.1 crore in the third quarter of the financial year 2024-25 (Q3FY25). During the same period in the previous financial year, the company reported a loss of Rs 16 crore. ...

What are the quarterly results of Biocon Ltd?

The Quarterly Results page of Biocon Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results. Rs 598.90Cr. Rs 80.60Cr. Rs 3.20Cr. Agg. Non-Promoter Share (Lakhs) Agg. Non-Promoter Holding (%) EPS (Rs.) Mutual fund SIP inflow at record high, but why is Nifty down 10% from peak? ...

How did Biocon perform in a quarter last year?

In the corresponding quarter last year, Biocon's earnings included revenue from the Branded Formulations India (BFI) business, which has since been divested, along with an income of ₹350 crore from the partial divestment of BFI units by Biocon Biologics and a gain of ₹456 crore from Biocon’s stake dilution in Bicara Therapeutics. ...

What is Biocon's stake in Biocon biologics?

Post this purchase, Biocon's stake in Biocon Biologics will be 90.2%. The purchase is expected to be completed on or before February 1, 2025, subject to the completion of necessary formalities. Biocon reported 96% year-on-year (YoY) drop in net profit to Rs 25 crore in Q3FY25. ...

How did Biocon biologics perform in the US biotech market?

The contract development and manufacturing organisation (CDMO), driven by biologics, saw positive momentum, indicating stabilising US biotech market dynamics, though later than expected. Biocon Biologics reported revenue from operations of Rs 2,289 crore, reflecting a 14 per cent yearly increase on a like-for-like basis. ...